Patents by Inventor Alessandro Boezio

Alessandro Boezio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250090540
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 20, 2025
    Inventors: Alessandro BOEZIO, Alexander M. TAYLOR, Hakan GUNAYDIN, Hanmo ZHANG, Kevin David RAYNOR, Kelley C. SHORTSLEEVES, Lucian V. DIPIETRO, Levi Charles Thomas PIERCE, Nicolas PABON, Thomas H. MCLEAN, Fabrizio GIORDANETTO, Yakov PECHERSKY, Qi WANG, Alexandre LARIVEE, Fei CHEN, Gaetan MAERTENS, Johanne OUTIN, Megan BERTRAND-LAPERLE, Mohan PAL, Sampada CHITALE, Michael Paul DENINNO
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250084048
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Ka enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Ka signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: October 7, 2022
    Publication date: March 13, 2025
    Inventors: Alessandro BOEZIO, Alexander M. TAYLOR, Junyi ZHANG, Kelley c. SHORTSLEEVES, Levi Charles Thomas PIERCE, Thomas H. MCLEAN, Anna KAPLAN, Amaël MADEC, Brandi M. HUDSON, Jun MA, Yue PAN, Gaetan MAERTENS, Johanne OUTIN
  • Substituted isoindolines as PI3K-alpha inhibitors
    Patent number: 12219327
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: February 4, 2025
    Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLC
    Inventors: Lucian V. Dipietro, Kelley C. Shortsleeves, Thomas H. Mclean, Alexandre Larivee, Fabrizio Giordanetto, André Lescarbeau, Alessandro Boezio, Hanmo Zhang
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250019380
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 16, 2025
    Inventors: Alessandro BOEZIO, Alexander M. TAYLOR, Cary Griffin FRIDRICH, Hakan GUNAYDIN, Lucian V. DIPIETRO, Levi Charles Thomas PIERCE, Mary M. MADER, Ravi KURUKULASURIYA, Thomas H. MCLEAN, Yue PAN, Michael Paul DENINNO, Alexandre LARIVEE, Andrew j. BURNIE, Caleb MEDENA, Gaetan MAERTENS, Kashif TANVEER, Mohan PAL, Tarek MOHAMED, Thomas LEPITRE, Bren-Jordan ATIENZA, Naresh VEMULA, Shorena GELOZIA
  • JAK2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240368122
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with JAK2 signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: August 19, 2022
    Publication date: November 7, 2024
    Inventors: Lucian V. DiPietro, Ravi Kurukulasuriya, Amael Madec, Catherine A. Evans, Cary Griffin Fridrich, Rebecca Jane Swett, Alessandro Boezio, Alexander M. Taylor, Thomas H. McLean, Christopher Thomson
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240287058
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 29, 2024
    Inventors: Alessandro BOEZIO, Lucian V. DIPIETRO, Cary Griffin FRIDRICH, Hakan GUNAYDIN, Ravi KURUKULASURIYA, André LESCARBEAU, Mary M. MADER, Thomas H. MCLEAN, Levi CharlesThomas PIERCE, Kevin David RAYNOR, Kelley C. SHORTSLEEVES, Yong TANG, Alexander M. TAYLOR, W. Patrick WALTERS, Hanmo ZHANG, Fabrizio GIORDANETTO, Yakov PECHERSKY, Qi WANG, Bren-Jordan ATIENZA, Megan BERTRAND-LAPERLE, Andrew J. BURNIE, Fei CHEN, Sampada CHITALE, Shorena GELOZIA, Jean-Benoit GIGUERE, Elodie LANDAGARAY, Alexandre LARIVEE, Thomas LEPITRE, Gaetan MAERTENS, Johanne OUTIN, Mohan PAL, Claudio STURINO, Kashif TANVEER, Rakesh THORAT, Naresh VEMULA, Elaine B. KRUEGER, Yue PAN, Michael Paul DENINNO, Yves BOUSQUET, Antoine JOBIN-DES LAURIERS, Jessica LEE, Tarek MOHAMED
  • CDK INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240190855
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 13, 2024
    Inventors: Alexander M. Taylor, Timothy F. Briggs, Nicolas A. Pabon, Jing He, Andre Lescarbeau, Alessandro Boezio, Catherine A. Evans, Cary Griffin Fridrich, Brian P. Kelley, Elaine B. Krueger, Ravi Kurukulasuriya, Thomas H. McLean
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20240158372
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 17, 2023
    Publication date: May 16, 2024
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 11780826
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 10, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent Dimassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • FGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230104574
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 12, 2020
    Publication date: April 6, 2023
    Inventors: Bakary-Barry TOURÉ, Heike SCHOENHERR, Alexander M. TAYLOR, Fabrizio GIORDANETTO, Demetri T. MOUSTAKAS, Thomas H. MCLEAN, Brandi M. HUDSON, Mary M. MADER, Pelin AYAZ, Dina A. SHARON, Ravi KURUKULASURIYA, Alessandro BOEZIO
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20220281850
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 8, 2022
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 11299479
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 12, 2022
    Assignees: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 10899746
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 26, 2021
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Bisamide sarcomere activating compounds and uses therof
    Patent number: 10723720
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 28, 2020
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20200223830
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20200223829
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Pyridine sulfonamides
    Patent number: 10668067
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, John R. Butler, Benjamin Charles Milgram, Gwenaella Rescourio, Alessandro Boezio, Brian Andrew Sparling, Daniel La
  • Bicyclic ketone sulfonamide compounds
    Patent number: 10472356
    Abstract: The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Benjamin Charles Milgram, Thomas Dineen, John Stellwagen, Angel Guzman-Perez, Alessandro Boezio, Issac E. Marx
  • PYRIDINE SULFONAMIDES
    Publication number: 20190167682
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: July 20, 2017
    Publication date: June 6, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, John R. BUTLER, Benjamin Charles MILGRAM, Gwenaella RESCOURIO, Alessandro BOEZIO, Brian Andrew SPARLING, Daniel LA
  • BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
    Publication number: 20190077793
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: September 13, 2018
    Publication date: March 14, 2019
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, JR., Richard Vargas, John Yeoman, Hanmo Zhang